US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Mira Pharma

1.22

-0.0100-0.81%

Post-market: 1.230.0096+0.79%18:58 EDT

Volume:85.13K

Turnover:103.47K

Market Cap:20.64M

PE:-2.45

High:1.28

Open:1.28

Low:1.20

Close:1.23

Loading ...

Overview Company News Filings

Mira Pharmaceuticals announces Ketamir-2 manuscript accepted for publication

MIRA Pharmaceuticals Announces Progress in Phase 1 Trial for Lead Drug Candidate Ketamir-2, Prepares for Phase 2a Initiation by Year-End 2025

Mira Pharmaceuticals Advances Ketamir-2 Development with SEC Regulatory Filings for SKNY Pharmaceuticals Acquisition

Mira Pharmaceuticals Inc. Announces Date for Virtual Special Meeting

Mira Pharmaceuticals Inc. Files Initial Statement of Beneficial Ownership for CFO Alan Weichselbaum

Visionstate Unveils MIRA to Revolutionize Facility Inspections

Mira Pharmaceuticals Nears Finalization of SKNY Pharmaceuticals Acquisition with Regulatory Filings Imminent

BRIEF-Mira Pharmaceuticals Inc - Michelle Yanez Steps Down As CFO Of Mira Pharmaceuticals - SEC Filing

MIRA Pharmaceuticals Appoints New Chief Financial Officer

BRIEF-Mira Pharmaceuticals Agrees To Acquire Skny Pharmaceuticals - SEC Filing

Mira Pharmaceuticals Inc - on April 30, Agreed to Acquire Skny Pharmaceuticals - SEC Filing

THOMSON REUTERS

MIRA Pharmaceuticals Acquires SKNY Pharmaceuticals, Boosting Enterprise Value to Over $60 Million

Mira Pharmaceuticals: Reports No Brain Toxicity in FDA-Required Study of Ketamir-2, Confirming Absence of Ketamine-Linked Neurotoxicity

THOMSON REUTERS

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

Market Exclusive

Psychedelic: Clearmind completes clinical site initiations for AUD trial

MIRA Pharmaceuticals Reports Positive In Vitro Drug Release Data for Topical Ketamir-2, Targeting $11B+ U.S. Topical Pain Relief Market and Exploring FDA Fast Track Designation

ACCESS Newswire

Top Midday Gainers

MT Newswires Live

MIRA Pharmaceuticals Announces Positive Results for Ketamir-2 in Diabetic Neuropathy Animal Model, Reinforcing Confidence Ahead of Phase I Completion

ACCESS Newswire

BRIEF-Mira Pharmaceuticals Inc - Announces Positive Study Results For Ketamir-2

Mira Pharmaceuticals Inc - Announces Positive Study Results for Ketamir-2 - SEC Filing

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/MIRA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MIRA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MIRA\",,,,,undefined,":{"symbol":"MIRA","market":"US","secType":"STK","nameCN":"Mira Pharma","latestPrice":1.22,"timestamp":1750449600000,"preClose":1.23,"halted":0,"volume":85132,"hourTrading":{"tag":"盘后","latestPrice":1.2296,"preClose":1.22,"latestTime":"18:58 EDT","volume":1765,"amount":2129.5516,"timestamp":1750460290463},"delay":0,"floatShares":13280306,"shares":16919623,"eps":-0.497709,"marketStatus":"Not Yet Opened","change":-0.01,"latestTime":"06-20 16:00:00 EDT","open":1.28,"high":1.28,"low":1.2,"amount":103469.560498,"amplitude":0.065041,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.497709,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1750665600000},"marketStatusCode":0,"adr":0,"listingDate":1691035200000,"exchange":"NASDAQ","adjPreClose":1.23,"preHourTrading":{"tag":"盘前","latestPrice":1.23,"preClose":1.23,"latestTime":"09:25 EDT","volume":1704,"amount":2094.577248,"timestamp":1750425900519},"postHourTrading":{"tag":"盘后","latestPrice":1.2296,"preClose":1.22,"latestTime":"18:58 EDT","volume":1765,"amount":2129.5516,"timestamp":1750460290463},"volumeRatio":0.38046616821756724},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MIRA\",,,,,undefined,":{"symbol":"MIRA","floatShares":13280306,"roa":"-193.30%","roe":"-355.82%","lyrEps":-0.508455,"volumeRatio":0.38046616821756724,"shares":16919623,"dividePrice":0,"high":1.28,"amplitude":0.065041,"preClose":1.23,"low":1.2,"week52Low":0.51,"pbRate":"15.95","week52High":5.01,"institutionHeld":0,"latestPrice":1.22,"eps":-0.497709,"divideRate":0,"volume":85132,"delay":0,"ttmEps":-0.497709,"open":1.28,"prevYearClose":1.14,"prevWeekClose":1.21,"prevMonthClose":1.35,"prevQuarterClose":0.98,"fiveDayClose":1.24,"twentyDayClose":1.21,"sixtyDayClose":1.22},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MIRA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2544977729","title":"Mira Pharmaceuticals announces Ketamir-2 manuscript accepted for publication","url":"https://stock-news.laohu8.com/highlight/detail?id=2544977729","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544977729?lang=en_us&edition=fundamental","pubTime":"2025-06-18 20:46","pubTimestamp":1750250777,"startTime":"0","endTime":"0","summary":"MIRA Pharmaceuticals (MIRA) announced that the first manuscript describing its lead drug candidate Ketamir-2, currently being evaluated in an ongoi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mira-pharmaceuticals-announces-ketamir-2-manuscript-accepted-for-publication-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mira-pharmaceuticals-announces-ketamir-2-manuscript-accepted-for-publication-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MIRA","BK4007"],"gpt_icon":0},{"id":"2544972759","title":"MIRA Pharmaceuticals Announces Progress in Phase 1 Trial for Lead Drug Candidate Ketamir-2, Prepares for Phase 2a Initiation by Year-End 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2544972759","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544972759?lang=en_us&edition=fundamental","pubTime":"2025-06-18 20:30","pubTimestamp":1750249851,"startTime":"0","endTime":"0","summary":"MIRA Pharmaceuticals Announces Progress in Phase 1 Trial for Lead Drug Candidate Ketamir-2, Prepares for Phase 2a Initiation by Year-End 2025. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via ACCESS Newswire  on June 18, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250618:nNDLc9fVmL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRA","BK4007"],"gpt_icon":0},{"id":"2544990199","title":"Mira Pharmaceuticals Advances Ketamir-2 Development with SEC Regulatory Filings for SKNY Pharmaceuticals Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2544990199","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544990199?lang=en_us&edition=fundamental","pubTime":"2025-06-18 04:02","pubTimestamp":1750190526,"startTime":"0","endTime":"0","summary":"Mira Pharmaceuticals Inc. recently announced progress in its regulatory endeavors, as the acquisition of SKNY Pharmaceuticals is advancing as planned. The company has successfully submitted the necessary regulatory filings for the merger to the U.S. Securities and Exchange Commission . This acquisition includes SKNY Pharmaceuticals' first-in-class oral CB1/CB2 inverse agonist for obesity and smoking cessation, SKNY-1. Furthermore, Mira Pharmaceuticals is on track to initiate a Phase 2a trial for Ketamir-2 in neuropathic pain by year-end 2025, pending regulatory clearance. This development marks a significant step in Mira Pharmaceuticals' clinical pipeline expansion.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals In","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250617:nNDL9vnzb9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRA","BK4007"],"gpt_icon":0},{"id":"2544962331","title":"Mira Pharmaceuticals Inc. Announces Date for Virtual Special Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2544962331","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544962331?lang=en_us&edition=fundamental","pubTime":"2025-06-17 20:03","pubTimestamp":1750161802,"startTime":"0","endTime":"0","summary":"MIRA Pharmaceuticals, Inc. is set to hold a virtual special meeting of its stockholders. Details regarding the specific date of the meeting have not been disclosed in the available information. During this meeting, stockholders will vote on proposals and resolutions brought forth by the board of directors. Further specifics about the proposals to be discussed or voted on have not been provided.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 17, 2025, and is solely responsible for the information contained there","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250617:nNDL9zLl33:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRA","BK4007"],"gpt_icon":0},{"id":"2542131621","title":"Mira Pharmaceuticals Inc. Files Initial Statement of Beneficial Ownership for CFO Alan Weichselbaum","url":"https://stock-news.laohu8.com/highlight/detail?id=2542131621","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542131621?lang=en_us&edition=fundamental","pubTime":"2025-06-10 19:13","pubTimestamp":1749554008,"startTime":"0","endTime":"0","summary":"Mira Pharmaceuticals Inc. has filed an initial statement of beneficial ownership. The filing identifies Alan Weichselbaum as the beneficial owner, who holds the position of Chief Financial Officer at the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 10, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250610:nNDL2qyH4m:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRA","BK4007"],"gpt_icon":0},{"id":"2541207140","title":"Visionstate Unveils MIRA to Revolutionize Facility Inspections","url":"https://stock-news.laohu8.com/highlight/detail?id=2541207140","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541207140?lang=en_us&edition=fundamental","pubTime":"2025-06-05 23:08","pubTimestamp":1749136092,"startTime":"0","endTime":"0","summary":"An announcement from Visionstate ( ($TSE:VIS) ) is now available. Visionstate Corp. has launched MIRA, a new software-as-a-service platform aimed a...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/visionstate-unveils-mira-to-revolutionize-facility-inspections?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/visionstate-unveils-mira-to-revolutionize-facility-inspections?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MIRA","BK4007"],"gpt_icon":0},{"id":"2538473062","title":"Mira Pharmaceuticals Nears Finalization of SKNY Pharmaceuticals Acquisition with Regulatory Filings Imminent","url":"https://stock-news.laohu8.com/highlight/detail?id=2538473062","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538473062?lang=en_us&edition=fundamental","pubTime":"2025-05-28 20:01","pubTimestamp":1748433677,"startTime":"0","endTime":"0","summary":"Mira Pharmaceuticals Inc. has announced progress in its acquisition of SKNY Pharmaceuticals Inc. The company is finalizing the necessary regulatory filings and expects to submit the required documentation to the U.S. Securities and Exchange Commission in the coming weeks. SKNY's lead development candidate, SKNY-1, focuses on smoking cessation and obesity treatment, targeting CB1, CB2, and MAO-B receptors. This acquisition is part of Mira's strategy to expand its portfolio and explore therapeutic areas with significant unmet needs.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval syste","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250528:nNDL5Z346N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MIRA"],"gpt_icon":0},{"id":"2537040952","title":"BRIEF-Mira Pharmaceuticals Inc - Michelle Yanez Steps Down As CFO Of Mira Pharmaceuticals - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2537040952","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537040952?lang=en_us&edition=fundamental","pubTime":"2025-05-22 06:42","pubTimestamp":1747867340,"startTime":"0","endTime":"0","summary":"BRIEF-Mira Pharmaceuticals Inc - Michelle Yanez Steps Down As CFO Of Mira Pharmaceuticals - SEC FilingMira Pharmaceuticals Inc MIRA.O:MIRA PHARMACEUTICALS INC - MICHELLE YANEZ STEPS DOWN AS CFO OF MIRA PHARMACEUTICALS - SEC FILINGMIRA PHARMACEUTICALS INC - ALAN WEICHSELBAUM APPOINTED AS CFO OF MIRA PHARMACEUTICALS - SEC FILINGSource text: [ID:n0001641172-25-011936]Further company coverage: MIRA.O","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250521:nFWN3RT3EO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRA"],"gpt_icon":0},{"id":"2537525479","title":"MIRA Pharmaceuticals Appoints New Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2537525479","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537525479?lang=en_us&edition=fundamental","pubTime":"2025-05-22 05:49","pubTimestamp":1747864174,"startTime":"0","endTime":"0","summary":"An update from MIRA Pharmaceuticals, Inc. ( ($MIRA) ) is now available. MIRA Pharmaceuticals, Inc. announced changes in its executive team with the...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mira-pharmaceuticals-appoints-new-chief-financial-officer?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mira-pharmaceuticals-appoints-new-chief-financial-officer?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MIRA","BK4007"],"gpt_icon":0},{"id":"2533813601","title":"BRIEF-Mira Pharmaceuticals Agrees To Acquire Skny Pharmaceuticals - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2533813601","media":"Reuters","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533813601?lang=en_us&edition=fundamental","pubTime":"2025-05-08 19:51","pubTimestamp":1746705100,"startTime":"0","endTime":"0","summary":"BRIEF-Mira Pharmaceuticals Agrees To Acquire Skny Pharmaceuticals - SEC FilingMay 8  - Mira Pharmaceuticals Inc MIRA.O:MIRA PHARMACEUTICALS INC - ON APRIL 30, AGREED TO ACQUIRE SKNY PHARMACEUTICALS - SEC FILINGMIRA PHARMACEUTICALS INC - COMBINED ENTERPRISE VALUE EXCEEDS $60 MILLION - SEC FILINGMIRA PHARMACEUTICALS INC -UNDER DEAL SKNY TO CONTRIBUTE $5 MILLION TO MIRA AT CLOSING - SEC FILINGSource text: [ID:n0001641172-25-009155]Further company coverage: MIRA.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250508:nFWN3RG1J0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRA","BK4007"],"gpt_icon":0},{"id":"2533418621","title":"Mira Pharmaceuticals Inc - on April 30, Agreed to Acquire Skny Pharmaceuticals - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2533418621","media":"THOMSON REUTERS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533418621?lang=en_us&edition=fundamental","pubTime":"2025-05-08 19:40","pubTimestamp":1746704423,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250508:nFWN3RG1J0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MIRA","BK4007"],"gpt_icon":0},{"id":"2533181211","title":"MIRA Pharmaceuticals Acquires SKNY Pharmaceuticals, Boosting Enterprise Value to Over $60 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2533181211","media":"Reuters","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533181211?lang=en_us&edition=fundamental","pubTime":"2025-05-08 19:31","pubTimestamp":1746703907,"startTime":"0","endTime":"0","summary":"Mira Pharmaceuticals Inc. has announced a definitive agreement to acquire SKNY Pharmaceuticals Inc., a biotechnology company specializing in therapies for obesity and nicotine dependence. The acquisition, unanimously approved by Mira's Board of Directors, follows independent valuations by Moore Financial Consulting, which valued SKNY at approximately $30.5 million and Mira at $30 million. As part of the transaction, SKNY will contribute $5 million in assets or cash to Mira upon closing. This strategic move is expected to bolster Mira's balance sheet and enhance its development initiatives, creating a combined enterprise with a value exceeding $60 million.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. publishe","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250508:nNDL1bmqqF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRA","BK4007"],"gpt_icon":0},{"id":"2533845126","title":"Mira Pharmaceuticals: Reports No Brain Toxicity in FDA-Required Study of Ketamir-2, Confirming Absence of Ketamine-Linked Neurotoxicity","url":"https://stock-news.laohu8.com/highlight/detail?id=2533845126","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533845126?lang=en_us&edition=fundamental","pubTime":"2025-05-06 19:34","pubTimestamp":1746531284,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250506:nFWN3RE1UU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MIRA","BK4007"],"gpt_icon":0},{"id":"2530468901","title":"Weekly Roundup on the Cannabis Sector & Psychedelic Sector","url":"https://stock-news.laohu8.com/highlight/detail?id=2530468901","media":"Market Exclusive","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530468901?lang=en_us&edition=fundamental","pubTime":"2025-04-28 03:31","pubTimestamp":1745782287,"startTime":"0","endTime":"0","summary":"Tilray announced plans to exit New Zealand medical cannabis market to focus on Australia. Village Farms was granted 180-day extension to regain Nasdaq listing requirements. SNDL launched “Rise Rewards” loyalty program to boost customer experience. Simply Solventless celebrated profitability at Humble Grow Co., surpassing projections. Cybin expanded clinical partnerships to accelerate phase 3 trial evaluating CYB003 for depression treatment. Compass Pathways completed dosing in phase 3 trial of COMP360 for treatment-resistant depression. Below is a weekly roundup of what happened this week in the cannabis and psychedelic sectors. In this ever-evolving landscape, we explore the major developments and groundbreaking initiatives happening among companies operating in these industries; from advancements in medical research, therapeutic applications to shifts in legal frameworks and current market trends.The New Zealand medical cannabis sector has faced challenges, particularly high regulato","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/weekly-roundup-cannabis-sector-psychedelic-193127070.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["T10G.NZ","USAW.SI","NQmain","CMPS","SNDL","TSYW.SI","CYBN","USJW.SI","BK4139","BK4007","BK4596","NZ50G.NZ","TLRY","PSQ","VFF","QID","ACB","TQQQ","MIRA","BK4547","QLD","SQQQ","NVIW.SI","NZ20C.NZ","BK4189",".IXIC","MNQmain","BK4557"],"gpt_icon":1},{"id":"2530215933","title":"Psychedelic: Clearmind completes clinical site initiations for AUD trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2530215933","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530215933?lang=en_us&edition=fundamental","pubTime":"2025-04-25 23:30","pubTimestamp":1745595026,"startTime":"0","endTime":"0","summary":"In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on site initiations, dosing completion and clinical site partnerships.Discover outperforming stocks and invest smarter with Top Smart Score Stocks.Filter, analyze, and streamline your search for investment opportunities using  Tipranks' Stock Screener.“AUD remains one of the most urgent and underserved public health challenges globally,” said Dr. Adi Zuloff-Shani, CEO. “With millions affected and current treatments often falling short, the study initiation for our FDA-approved CMND-100 trial marks a critical step toward potentially transforming the treatment landscape for alcoholism. We are honored to collaborate with world renowned institutions such as Yale and Johns Hopkins as we advance our mission to potentially provide safe, effective, and innovative solutions for individuals those suffering from alcoholism.”“Completing dosing of all participants in Part A of our 005 tria","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/psychedelic-clearmind-completes-clinical-initiations-153026935.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/psychedelic-clearmind-completes-clinical-initiations-153026935.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["FLHLF","KTTA","BK4202","BK4168","MIRA","RLMD","ALID","BK4139","AGNPF","CYBN","MDXXF","ENTBF","CMPS","BK4007","SNPX","RVVTF","NUMIF","OPTHF","ATAI","QNTM","MNMD","SILO","BK4539","ENVB","SEEL","BETRF","CMND","BK4547","NRXP","PHRRF","IXHL","MYCOF","PSYGF","GHRS","PBM","SPRC","DRUG"],"gpt_icon":0},{"id":"2529504063","title":"MIRA Pharmaceuticals Reports Positive In Vitro Drug Release Data for Topical Ketamir-2, Targeting $11B+ U.S. Topical Pain Relief Market and Exploring FDA Fast Track Designation","url":"https://stock-news.laohu8.com/highlight/detail?id=2529504063","media":"ACCESS Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529504063?lang=en_us&edition=fundamental","pubTime":"2025-04-23 20:00","pubTimestamp":1745409600,"startTime":"0","endTime":"0","summary":"MIAMI, FLORIDA / ACCESS Newswire / April 23, 2025 / MIRA Pharmaceuticals, Inc. , or MIRA, a clinical-stage pharmaceutical company focused on developing novel therapeutics for neurologic and neuropsychiatric disorders, today announced the completion of in vitro release testing  for its topical formulation of Ketamir-2. The formulation is under investigation for localized application in pain-related conditions.\"As we continue expanding the Ketamir-2 program, we remain committed to building long-term shareholder value through strategic innovation and disciplined execution,\" said Erez Aminov, Chairman and CEO of MIRA. \"The ability to develop both oral and a localized topical formulation positions us to address a much broader segment of the pain market, which represents a significant commercial opportunity and a clear path for differentiation in a space that urgently needs safer, more targeted treatment options.\". MIRA is currently advancing preclinical studies to evaluate the topical formu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mira-pharmaceuticals-reports-positive-vitro-120000673.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4104","BK4588","FAST","MIRA","BK4567","BK4007","IE00B5TLWC47.USD","IE00BFXG0V08.USD","IE00BYQQ9H92.USD","BK4585"],"gpt_icon":1},{"id":"2528275805","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2528275805","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528275805?lang=en_us&edition=fundamental","pubTime":"2025-04-17 02:05","pubTimestamp":1744826711,"startTime":"0","endTime":"0","summary":"RadNet  has agreed to acquire iCad  in an all-stock deal valued at roughly $103 million, they said late Tuesday.Shares of iCad soared 71%, with intraday trading volume of over 17.2 million from a daily average of about 508,000.Treasure Global  struck a partnership with Mezzofy , securing distribution rights for Mezzofy's digital coupon platform in Malaysia. It expects to generate $2 million to $4 million in annual revenue in the first 12 months of the rollout.Shares surged 57% as intraday trading volume soared to more than 92 million from a daily average of about 354,000.Mira Pharmaceuticals  said Wednesday that data demonstrated the potential efficacy of its oral ketamine analog, Ketamir-2, in treating diabetic neuropathy in an animal model.Shares advanced 15%, with intraday trading volume rising to over 44.8 million from a daily average of about 255,000.Price: 50.78, Change: -2.30, Percent Change: -4.33","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ICAD","MIRA","BK4167","BK4009","BK4196","BK4007","LU2065731478.USD","TGL","RDNT"],"gpt_icon":1},{"id":"2527221611","title":"MIRA Pharmaceuticals Announces Positive Results for Ketamir-2 in Diabetic Neuropathy Animal Model, Reinforcing Confidence Ahead of Phase I Completion","url":"https://stock-news.laohu8.com/highlight/detail?id=2527221611","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527221611?lang=en_us&edition=fundamental","pubTime":"2025-04-16 20:00","pubTimestamp":1744804800,"startTime":"0","endTime":"0","summary":"Ketamir-2 Demonstrates Strong Efficacy in Diabetic Neuropathy Model, with Some Subjects Achieving Complete Symptom Reversal. MIAMI, FLORIDA / ACCESS Newswire / April 16, 2025 / MIRA Pharmaceuticals, Inc. , or MIRA, a clinical-stage pharmaceutical company focused on developing novel therapeutics for neurologic and neuropsychiatric disorders, today announced compelling data demonstrating the efficacy of the oral ketamine analog, Ketamir-2, in a validated animal model of diabetic neuropathy.In the study, Type 2 diabetes was induced in rats using a high-fat diet combined with a low dose of Streptozotocin . This resulted in hyperglycemia and neuropathic symptoms, including hyperalgesia and allodynia, mimicking human diabetic pathology. By week 8, most diabetic rats exhibited sensory hypersensitivity. Treatment with Ketamir-2 led to a significant reduction in neuropathic pain symptoms, with some animals returning completely to pre-diabetic baseline sensitivity. \"Millions of patients with dia","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mira-pharmaceuticals-announces-positive-results-120000582.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2552382058.USD","BK4588","BK4504","BK4007","LU2552382132.HKD","BK4169","MIRA","LU2552382215.SGD","STZ","BK4585","BK4559"],"gpt_icon":0},{"id":"2527290559","title":"BRIEF-Mira Pharmaceuticals Inc - Announces Positive Study Results For Ketamir-2","url":"https://stock-news.laohu8.com/highlight/detail?id=2527290559","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527290559?lang=en_us&edition=fundamental","pubTime":"2025-04-16 19:35","pubTimestamp":1744803308,"startTime":"0","endTime":"0","summary":"BRIEF-Mira Pharmaceuticals Inc - Announces Positive Study Results For Ketamir-2April 16  - Mira Pharmaceuticals Inc MIRA.O:MIRA PHARMACEUTICALS INC - ANNOUNCES POSITIVE STUDY RESULTS FOR KETAMIR-2 - SEC FILINGMIRA PHARMACEUTICALS INC - KETAMIR-2 SHOWS SIGNIFICANT REDUCTION IN NEUROPATHIC PAIN SYMPTOMS - SEC FILINGMIRA PHARMACEUTICALS INC - TO INITIATE PHASE IIA TRIAL IN DIABETIC NEUROPATHY PATIENTS BY END OF 2025Further company coverage: MIRA.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250416:nFWN3QU0Y9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRA","BK4007"],"gpt_icon":0},{"id":"2527977472","title":"Mira Pharmaceuticals Inc - Announces Positive Study Results for Ketamir-2 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2527977472","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527977472?lang=en_us&edition=fundamental","pubTime":"2025-04-16 19:31","pubTimestamp":1744803111,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250416:nFWN3QU0Y9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MIRA","BK4007"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":56,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MIRA\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MIRA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MIRA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":1,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":1,"analysts":1,"updateTime":1741233600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/MIRA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"MIRA","date":"2025-06-20","current":-2.628111,"percent":0.260674,"low":-15.501022,"twenty":-2.999889,"median":-1.99311,"eighty":-1.352726,"high":-0.648567,"avg":-3.268332,"sd":3.439237,"marketCap":20811136},"quantilePoints":[{"date":"2023-08-04","current":-15.501022,"twenty":-15.501022,"median":-15.501022,"eighty":-15.501022,"marketCap":109409161},{"date":"2023-08-11","current":-14.407729,"twenty":-14.826558,"median":-14.407729,"eighty":-13.088417,"marketCap":101692488},{"date":"2023-08-18","current":-13.611953,"twenty":-14.407729,"median":-13.779485,"eighty":-13.130299,"marketCap":96075752},{"date":"2023-08-25","current":-13.193124,"twenty":-14.407729,"median":-13.42348,"eighty":-13.109358,"marketCap":93119575},{"date":"2023-09-01","current":-13.137838,"twenty":-14.303022,"median":-13.371126,"eighty":-13.130299,"marketCap":92729360},{"date":"2023-09-07","current":-12.209294,"twenty":-13.9889,"median":-13.365891,"eighty":-13.071664,"marketCap":86175515},{"date":"2023-09-15","current":-7.434221,"twenty":-13.678966,"median":-13.193124,"eighty":-12.686741,"marketCap":52472141},{"date":"2023-09-22","current":-11.507289,"twenty":-13.511434,"median":-13.119829,"eighty":-11.928492,"marketCap":66366173},{"date":"2023-09-29","current":-12.263336,"twenty":-13.419292,"median":-13.046534,"eighty":-11.42538,"marketCap":70726534},{"date":"2023-10-06","current":-12.045492,"twenty":-13.402539,"median":-12.816178,"eighty":-11.507289,"marketCap":69470159},{"date":"2023-10-13","current":-7.586097,"twenty":-13.383691,"median":-12.460173,"eighty":-11.225373,"marketCap":43751419},{"date":"2023-10-20","current":-8.457473,"twenty":-13.371126,"median":-12.263336,"eighty":-10.752267,"marketCap":48776920},{"date":"2023-10-27","current":-6.022746,"twenty":-13.371126,"median":-12.209294,"eighty":-9.627991,"marketCap":34735079},{"date":"2023-11-03","current":-3.818677,"twenty":-13.36275,"median":-12.045492,"eighty":-8.098671,"marketCap":22023518},{"date":"2023-11-10","current":-3.793048,"twenty":-13.343902,"median":-11.968606,"eighty":-7.418465,"marketCap":21875709},{"date":"2023-11-17","current":-6.622011,"twenty":-13.222442,"median":-11.712319,"eighty":-5.991992,"marketCap":49959391},{"date":"2023-11-24","current":-6.405718,"twenty":-13.159952,"median":-11.404903,"eighty":-6.252529,"marketCap":48327581},{"date":"2023-12-01","current":-6.955071,"twenty":-13.133315,"median":-11.148487,"eighty":-6.405718,"marketCap":52472141},{"date":"2023-12-08","current":-3.546106,"twenty":-13.117734,"median":-10.762135,"eighty":-5.961237,"marketCap":26753401},{"date":"2023-12-15","current":-2.977946,"twenty":-13.096793,"median":-9.110163,"eighty":-5.156496,"marketCap":22466945},{"date":"2023-12-22","current":-2.066929,"twenty":-13.063287,"median":-8.611245,"eighty":-3.869935,"marketCap":15593833},{"date":"2023-12-29","current":-2.155092,"twenty":-13.025592,"median":-8.1243,"eighty":-3.839181,"marketCap":16258973},{"date":"2024-01-05","current":-2.272643,"twenty":-12.962768,"median":-7.893642,"eighty":-3.762396,"marketCap":17145826},{"date":"2024-01-12","current":-1.929591,"twenty":-12.874813,"median":-7.640782,"eighty":-3.079823,"marketCap":14557693},{"date":"2024-01-19","current":-1.608482,"twenty":-12.807801,"median":-7.444864,"eighty":-2.883906,"marketCap":12135106},{"date":"2024-01-26","current":-2.292235,"twenty":-12.642964,"median":-7.355439,"eighty":-2.366683,"marketCap":17293635},{"date":"2024-02-02","current":-1.880808,"twenty":-12.498268,"median":-7.111805,"eighty":-2.256969,"marketCap":14189649},{"date":"2024-02-09","current":-1.950359,"twenty":-12.397348,"median":-6.788541,"eighty":-2.206031,"marketCap":14714371},{"date":"2024-02-16","current":-2.01795,"twenty":-12.300188,"median":-6.405718,"eighty":-2.186439,"marketCap":15224311},{"date":"2024-02-23","current":-2.076725,"twenty":-12.241719,"median":-6.022746,"eighty":-2.135501,"marketCap":15667738},{"date":"2024-03-01","current":-1.968971,"twenty":-12.205282,"median":-5.750179,"eighty":-2.104154,"marketCap":14854789},{"date":"2024-03-08","current":-1.86102,"twenty":-12.137755,"median":-4.971969,"eighty":-2.061052,"marketCap":14040362},{"date":"2024-03-15","current":-2.409785,"twenty":-12.045492,"median":-3.957585,"eighty":-2.070847,"marketCap":18180488},{"date":"2024-03-22","current":-2.46856,"twenty":-12.014738,"median":-3.869935,"eighty":-2.084562,"marketCap":18623915},{"date":"2024-03-28","current":-2.135501,"twenty":-11.968606,"median":-3.818677,"eighty":-2.096317,"marketCap":16111164},{"date":"2024-04-05","current":-1.258227,"twenty":-11.958355,"median":-3.592948,"eighty":-2.059093,"marketCap":15076502},{"date":"2024-04-12","current":-1.209008,"twenty":-11.917349,"median":-3.095496,"eighty":-2.037542,"marketCap":14486745},{"date":"2024-04-19","current":-1.033719,"twenty":-11.835337,"median":-3.026925,"eighty":-1.978767,"marketCap":12386381},{"date":"2024-04-26","current":-1.1102,"twenty":-11.507289,"median":-2.977946,"eighty":-1.941738,"marketCap":13302796},{"date":"2024-05-03","current":-0.996589,"twenty":-11.466334,"median":-2.723253,"eighty":-1.872971,"marketCap":11941476},{"date":"2024-05-10","current":-0.925167,"twenty":-11.297339,"median":-2.546927,"eighty":-1.840684,"marketCap":11085663},{"date":"2024-05-17","current":-0.812651,"twenty":-11.251002,"median":-2.419581,"eighty":-1.782849,"marketCap":10043611},{"date":"2024-05-24","current":-1.05244,"twenty":-11.138236,"median":-2.390193,"eighty":-1.612165,"marketCap":13007178},{"date":"2024-05-31","current":-0.956764,"twenty":-11.09723,"median":-2.331418,"eighty":-1.319904,"marketCap":11824708},{"date":"2024-06-07","current":-0.922081,"twenty":-10.81147,"median":-2.30203,"eighty":-1.233679,"marketCap":11396062},{"date":"2024-06-14","current":-0.849247,"twenty":-10.732533,"median":-2.292235,"eighty":-1.18937,"marketCap":10495906},{"date":"2024-06-21","current":-0.875439,"twenty":-10.189973,"median":-2.272643,"eighty":-1.090284,"marketCap":10819607},{"date":"2024-06-28","current":-0.77737,"twenty":-9.841423,"median":-2.272643,"eighty":-1.073193,"marketCap":9607575},{"date":"2024-07-05","current":-0.687674,"twenty":-9.256415,"median":-2.262847,"eighty":-1.05424,"marketCap":8499008},{"date":"2024-07-12","current":-0.717692,"twenty":-8.841445,"median":-2.213868,"eighty":-1.045463,"marketCap":8870009},{"date":"2024-07-15","current":-0.704656,"twenty":-8.774265,"median":-2.213868,"eighty":-1.033719,"marketCap":8708897},{"date":"2024-08-02","current":-2.906169,"twenty":-8.772416,"median":-2.213868,"eighty":-1.036655,"marketCap":35917550},{"date":"2024-08-09","current":-2.535423,"twenty":-8.703509,"median":-2.262847,"eighty":-1.048424,"marketCap":31335476},{"date":"2024-08-16","current":-2.173611,"twenty":-8.390838,"median":-2.272643,"eighty":-1.04904,"marketCap":27788063},{"date":"2024-08-23","current":-2.162049,"twenty":-8.098671,"median":-2.248016,"eighty":-1.051378,"marketCap":27640254},{"date":"2024-08-30","current":-2.162049,"twenty":-7.95515,"median":-2.242981,"eighty":-1.05289,"marketCap":27640254},{"date":"2024-09-06","current":-1.826758,"twenty":-7.791127,"median":-2.23142,"eighty":-1.05469,"marketCap":23353798},{"date":"2024-09-13","current":-1.549276,"twenty":-7.650578,"median":-2.222644,"eighty":-1.05842,"marketCap":19806385},{"date":"2024-09-20","current":-1.341164,"twenty":-7.640782,"median":-2.194276,"eighty":-1.060611,"marketCap":17145826},{"date":"2024-09-27","current":-1.237108,"twenty":-7.586097,"median":-2.16783,"eighty":-1.073193,"marketCap":15815546},{"date":"2024-10-04","current":-1.352726,"twenty":-7.444864,"median":-2.155092,"eighty":-1.083185,"marketCap":17293635},{"date":"2024-10-11","current":-1.24867,"twenty":-7.434221,"median":-2.147009,"eighty":-1.095016,"marketCap":15963355},{"date":"2024-10-18","current":-1.260232,"twenty":-7.355439,"median":-2.135501,"eighty":-1.1102,"marketCap":16111164},{"date":"2024-10-25","current":-1.437761,"twenty":-7.355439,"median":-2.125705,"eighty":-1.110817,"marketCap":18380747},{"date":"2024-10-31","current":-2.79918,"twenty":-7.270245,"median":-2.125705,"eighty":-1.18937,"marketCap":35785525},{"date":"2024-11-08","current":-2.150279,"twenty":-7.139233,"median":-2.135501,"eighty":-1.21299,"marketCap":27489790},{"date":"2024-11-15","current":-2.170683,"twenty":-7.064784,"median":-2.135501,"eighty":-1.218696,"marketCap":24399222},{"date":"2024-11-22","current":-1.856409,"twenty":-6.974663,"median":-2.135501,"eighty":-1.224412,"marketCap":20866673},{"date":"2024-11-29","current":-1.90061,"twenty":-6.755235,"median":-2.115909,"eighty":-1.229612,"marketCap":21363499},{"date":"2024-12-06","current":-1.753275,"twenty":-6.551481,"median":-2.101597,"eighty":-1.233136,"marketCap":19707413},{"date":"2024-12-13","current":-1.650142,"twenty":-6.445215,"median":-2.081117,"eighty":-1.235736,"marketCap":18548154},{"date":"2024-12-20","current":-1.473341,"twenty":-6.405718,"median":-2.071827,"eighty":-1.237108,"marketCap":16560852},{"date":"2024-12-27","current":-1.768009,"twenty":-6.252529,"median":-2.060335,"eighty":-1.241733,"marketCap":19873022},{"date":"2025-01-03","current":-1.694342,"twenty":-5.991992,"median":-2.057134,"eighty":-1.250581,"marketCap":19044979},{"date":"2025-01-10","current":-1.959543,"twenty":-5.868974,"median":-2.057134,"eighty":-1.258227,"marketCap":22025933},{"date":"2025-01-17","current":-1.768009,"twenty":-5.779566,"median":-2.037542,"eighty":-1.258227,"marketCap":19873022},{"date":"2025-01-24","current":-1.664875,"twenty":-5.732546,"median":-2.035768,"eighty":-1.259831,"marketCap":18713762},{"date":"2025-01-31","current":-1.856409,"twenty":-5.367769,"median":-2.010846,"eighty":-1.260232,"marketCap":20866673},{"date":"2025-02-07","current":-1.723809,"twenty":-5.033478,"median":-1.997597,"eighty":-1.260232,"marketCap":19376196},{"date":"2025-02-14","current":-1.753275,"twenty":-4.268723,"median":-1.967235,"eighty":-1.268496,"marketCap":19707413},{"date":"2025-02-21","current":-1.635408,"twenty":-4.064306,"median":-1.959359,"eighty":-1.271301,"marketCap":18382545},{"date":"2025-02-28","current":-1.502808,"twenty":-3.940055,"median":-1.950359,"eighty":-1.271793,"marketCap":16892069},{"date":"2025-03-07","current":-1.488074,"twenty":-3.869935,"median":-1.934829,"eighty":-1.271793,"marketCap":16726460},{"date":"2025-03-14","current":-1.841676,"twenty":-3.869935,"median":-1.920187,"eighty":-1.27873,"marketCap":20701065},{"date":"2025-03-21","current":-1.797476,"twenty":-3.846869,"median":-1.893243,"eighty":-1.290292,"marketCap":20204239},{"date":"2025-03-28","current":-1.620675,"twenty":-3.823803,"median":-1.885876,"eighty":-1.294917,"marketCap":18216937},{"date":"2025-04-04","current":-1.927027,"twenty":-3.8033,"median":-1.893243,"eighty":-1.309909,"marketCap":15132288},{"date":"2025-04-11","current":-1.806267,"twenty":-3.701093,"median":-1.885876,"eighty":-1.319904,"marketCap":14183998},{"date":"2025-04-17","current":-2.291021,"twenty":-3.602316,"median":-1.885876,"eighty":-1.323783,"marketCap":17990609},{"date":"2025-04-25","current":-2.128723,"twenty":-3.467739,"median":-1.885876,"eighty":-1.330657,"marketCap":16716134},{"date":"2025-05-02","current":-2.440901,"twenty":-3.248312,"median":-1.90061,"eighty":-1.333733,"marketCap":19167565},{"date":"2025-05-09","current":-2.676427,"twenty":-3.087659,"median":-1.92061,"eighty":-1.335972,"marketCap":21017067},{"date":"2025-05-16","current":-3.015077,"twenty":-3.060231,"median":-1.929591,"eighty":-1.33782,"marketCap":23875388},{"date":"2025-05-23","current":-2.611651,"twenty":-3.060231,"median":-1.942197,"eighty":-1.340821,"marketCap":20680794},{"date":"2025-05-30","current":-2.845213,"twenty":-3.032803,"median":-1.954767,"eighty":-1.341164,"marketCap":22530296},{"date":"2025-06-06","current":-2.927246,"twenty":-3.016719,"median":-1.959543,"eighty":-1.343476,"marketCap":23179883},{"date":"2025-06-13","current":-2.649478,"twenty":-3.012039,"median":-1.970481,"eighty":-1.352726,"marketCap":20980332},{"date":"2025-06-20","current":-2.628111,"twenty":-2.999889,"median":-1.99311,"eighty":-1.352726,"marketCap":20811136}],"updateTime":1750620714221}}}